Tyrogenex Information

Tyrogenex has developed X-82, an orally administered, dual VEGFR/PDGFR inhibitor, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study shows that X-82 is well tolerated, does not exhibit any dose-limiting toxicity and demonstrates preliminary signs of anti-tumor activity. The company has initiated phase 2 studies of X-82 for both wet AMD and solid tumors in 2015.

Website	https://www.tyrogenex.com
Revenue	$1.6 million
Employees	2 (0 on RocketReach)
Founded	2006
Address	155 Gibbs St Ste 403, Rockville, Maryland 20850, US
Phone	+1 855-978-7025
Technologies	DNS Made Easy (view technologies)
Industry	Biotechnology, Business Services General, Wet Age-related macular degeneration (AMD), Business Services, Science and Engineering, Solid Tumors, Medical Device, Health Care, Therapeutics
Keywords	Targeted Therapy, Cancer Treatment, Ophthalmic Drugs, Clinical Trials, Phase 1 Trials, Phase 2 Trials, Drug Development, Pharmaceutical Research, Oncology, Ophthalmology, Solid Tumors, Biotechnology, Medicine
Competitors	Roche, Novartis, Merck & Co., Inc., Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences, Lilly India +36 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 54 Companies